孕中期母血清胎盘蛋白13作为预测子痫前期标记物的初步研究

Preliminary study of placental protein 13 as a maternal serum marker for preeclampsia in second-trimester

目的:探讨孕中期(16～18周)孕妇血清胎盘蛋白13(PP13)水平变化对子痫前期(PE)的预测价值。方法:选取22例PE患者(病例组)和55例正常孕妇(对照组),于孕16～18周行唐氏筛查的同时采用时间分辨荧光免疫技术(DEFILA)检测两组孕妇的血清PP13水平。结果:孕16、17、18周时对照组孕妇的PP13中位数分别为47.5、49和51.2pmol/L,随着孕周增加而增加(r=1.0,P<0.01);病例组孕妇的PP13中位数分别为52.7、46.7和42.9pmol/L,随着孕周增加而下降(r=-1.0,P<0.01)。血清PP13水平用MOM值表示,病例组与对照组无显著差异(1.04MOM vs 1.00MOM,P>0.05)。结论:孕16～18周时孕妇血清PP13的单次检测不能预测PE,但连续监测可能对预测PE有一定的价值。

Objective：To evaluate the value of second-trimester maternal serum placen- tal protein 13 （ PP13 ） as a maternal serum marker for preeclampsia prediction. Methods： The maternal serum PP13 concentrations were measured by method of time-resolved fluorescence immunoassay （DEIFIA） in serum samples that were collected from 77 pregnant women with 16,17 and 18 weeks of gestation when they were screened for Down syndrome. 55 women with normal pregnancy were classified as control group and 22 women with preeclampsia were recrui- ted as case group. Results ：Median PP13 concentration in 16,17 and 18 weeks of gestation were 47.5pmol/L,49pmol/L,51.2pmol/L in control group and 52.7pmoL/L,46.7pmol/L and 42.9 pmol/L in case group respectively. PP13 concentration increased with gestational weeks in control group and decreased in case group（ P〈0.05 ） , and there was no significantly difference be- tween the two groups（ 1.04MOM vs 1. OOMOM ,P〉0.05）. Conclusions： Only PP13 in the ser- um of pregnant women is not a valuable marker for predicting preeclampsia from 16 to 18 weeks of gestation ,but continuous detection of maternal serum PP13 may be useful.